Technology Bundle ID: TAB-2729

Immunogenic Hepatitis E Virus Polypeptides for Vaccine and Diagnostics Development

Request More Info
Primary Inventors: 
Howard Fields (CDC)
Co-Inventors: 
Jihong Meng (CDC), Yury Khudyakov (CDC)
Development Stage: 
Pre-Clinical (in vitro)
Development Status: 

In vitro data available

Institute or Center: 
CDC

This technology comprises specific hepatitis E virus (HEV) antigenic polypeptides. HEV causes epidemic and sporadic cases of hepatitis outbreaks with a mortality rate as high as 20% for pregnant women. In order to address this problem, CDC scientists carried out thorough HEV antigen screenings and subsequently developed recombinant proteins that efficiently model major HEV neutralization epitope(s). These recombinant proteins may be considered as candidates for the development of an HEV subunit vaccine, as well as for the development of highly sensitive and specific diagnostic tests.

Applications:
  • Development of a peptide subunit-based vaccine for hepatitis E virus (HEV)
  • Development of HEV sero-diagnostic tools and reagents
  • Blood transfusion screening
  • Pregnancy screening safety precautions
  • Hepatitis monitoring programs
  • Basic research into hepatitis pathogenicity and immune response
Advantages:
  • Generated antibodies were cross-reactive with a number of geographically distinct HEV strains
  • Useful for development of highly sensitive and specific diagnostic tests
  • Could be useful for improving efficacy and HEV-strain immunity provided by current vaccine(s)

Patents

PCT Application PCT/US01/010696
Filed on 2001-04-03
US Application 10/257,044
Filed on 2001-04-03
US Application 60/195,380
Filed on 2000-04-07

Various international patents issued

Publications

Meng J, et al.
PMID 11601892

Updated

Jan 20, 2014

Data Source: 
tts